These data confirm the debilitating effects of apathy on functioning in patients with Huntington disease.
The authors noted that apathy is very common and progressive among Huntington disease mutation carriers, even during early stages of the disease, and has been associated with decline in general functioning.
Electrical stimulation of the amygdala may boost declarative memory without influencing an emotional response.
The HD-associated CAG repeat with 36 or more repeats was found in 18 individuals.
The FDA has accepted Teva's New Drug Application for deutetrabenazine to treat chorea associated with Huntington's disease.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Mood Stabilizers Associated With Increased Risk for Stroke in Bipolar Disorder
- Methylphenidate for ADHD Treatment May Be Associated With Low BMI
- Patients With Schizophrenia May Benefit From Occupational Therapy
- FDA Committees Vote on Opioid System Modulator for MDD Treatment
- Minocycline vs Routine Care for Clinical Symptom Improvement in Schizophrenia
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- Opioid Use Often Persists in Workers' Compensation Claimants
- Parental Mental Disorders Linked to Work Disabilities in Offspring
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- Mortality Rates in Parkinson Disease Psychosis With Pimavanserin, Quetiapine